On December 23, 2024, China’s NMPA officially approved the new drug application ofStapokibart Injection, a Class 1 innovative biologic developed by KeyMed Biosciences, for the ...
On December 20, 2024, the official website of China's National Medical Products Administration (NMPA) announced that the marketing application for taletrectinib adipate capsul...
On September 25, 2024, the official website of China's National Medical Products Administration (NMPA) announced that the New Drug Application for an paclitaxel oral solution, ...
On June 24, 2024, Haihe Biopharma announced that its self-developed oral small-molecule MET inhibitor, Glumetinib, has been successfully approved by Japan's Ministry of Health,...
On 25 November 2021, 3D Medicines (Beijing) Co., Ltd. (3DMed), Alphamab Oncology, and Simcere Pharmaceutical Group Limited (Simcere) jointly announced that Envafolimab (KN035), the...
Shanghai, China – March 19, 2020 – Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, announced that the National Med...
Shanghai Office
Rm 208, Building 1, Universal Science & Technology Plaza, No. 958 Zhenbei Rd, Shanghai, China
Hanzhou Office
Rm 1802, Fl.18, Building 8, No. 19, Jugong Rd, Xixing Street, Binjiang District, Hangzhou, China
Jiaxing Office
No. 551, Yazhong Rd, Nanhu District, Jiaxing, China
FAB Japan
8F, 1 Chome-5-1 Kanda Ogawamachi, Chiyoda City, Tokyo 101-0052
Follow Us
Home
Services
Telephone
Message